{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:48:22Z","timestamp":1768009702374,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10620-025-09125-5","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:19:33Z","timestamp":1749856773000},"page":"3120-3125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patients with Crohn\u2019s Disease and Ileostomy Can Respond to Upadacitinib"],"prefix":"10.1007","volume":"70","author":[{"given":"Lauren","family":"Loeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami A.","family":"Kinnucan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Picco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"9125_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","volume":"64","author":"M Gajendran","year":"2018","unstructured":"Gajendran M, Loganathan P, Catinella AP et al. A comprehensive review and update on Crohn\u2019s disease. Dis Mon 2018;64:20\u201357.","journal-title":"Dis Mon"},{"key":"9125_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2019.02.004","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G et al. A comprehensive review and update on ulcerative colitis. Dis Mon 2019;65:100851.","journal-title":"Dis Mon"},{"key":"9125_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","volume":"14","author":"MP Sparrow","year":"2020","unstructured":"Sparrow MP, Papamichael K, Ward MG et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis 2020;14:542\u2013556.","journal-title":"J Crohns Colitis"},{"key":"9125_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","volume":"14","author":"SC Shah","year":"2016","unstructured":"Shah SC, Colombel JF, Sands BE et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245\u201355.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9125_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","volume":"21","author":"K Papamichael","year":"2015","unstructured":"Papamichael K, Gils A, Rutgeerts P et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2015;21:182\u2013197.","journal-title":"Inflamm Bowel Dis"},{"key":"9125_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","volume":"4","author":"M Allez","year":"2010","unstructured":"Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355\u2013366.","journal-title":"J Crohns Colitis"},{"key":"9125_CR7","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol 2020;18:2179-2191.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9125_CR8","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020;158:2139-2149.e14.","journal-title":"Gastroenterology"},{"key":"9125_CR9","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology 2020;158:2123-2138.e8.","journal-title":"Gastroenterology"},{"key":"9125_CR10","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 2023;388:1966\u20131980.","journal-title":"N Engl J Med"},{"key":"9125_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022;399:2113\u20132128.","journal-title":"Lancet"},{"key":"9125_CR12","doi-asserted-by":"publisher","first-page":"ii45","DOI":"10.1093\/rheumatology\/keaa896","volume":"60","author":"C Harris","year":"2021","unstructured":"Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxf) 2021;60:ii45\u2013ii51.","journal-title":"Rheumatology (Oxf)"},{"key":"9125_CR13","doi-asserted-by":"publisher","first-page":"S711","DOI":"10.1093\/ecco-jcc\/jjaa109","volume":"14","author":"J Pan\u00e9s","year":"2020","unstructured":"Pan\u00e9s J, Vermeire S. JAK inhibitors: back to small molecules for the treatment of IBD. J Crohns Colitis 2020;14:S711\u2013S712.","journal-title":"J Crohns Colitis"},{"key":"9125_CR14","doi-asserted-by":"publisher","first-page":"100955","DOI":"10.1016\/j.scrs.2023.100955","volume":"34","author":"HJ Boutte","year":"2023","unstructured":"Boutte HJ, Poylin V. High ileostomy output: a practical review of pathophysiology, causes, and management. Semin Colon Rectal Surg 2023;34:100955.","journal-title":"Semin Colon Rectal Surg"},{"key":"9125_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/gut.25.4.365","volume":"25","author":"RC Spiller","year":"1984","unstructured":"Spiller RC, Trotman IF, Higgins BE et al. The ileal brake\u2014inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984;25:365\u2013374.","journal-title":"Gut"},{"key":"9125_CR16","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.clnu.2018.07.036","volume":"37","author":"L Pironi","year":"2018","unstructured":"Pironi L, Corcos O, Forbes A et al. Intestinal failure in adults: recommendations from the ESPEN Expert Groups. Clin Nutr 2018;37:1798\u20131809.","journal-title":"Clin Nutr"},{"key":"9125_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0016-5085(03)70064-X","volume":"124","author":"AL Buchman","year":"2003","unstructured":"Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1111\u20131134.","journal-title":"Gastroenterology"},{"key":"9125_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.suc.2019.08.010","volume":"99","author":"MA Fuglestad","year":"2019","unstructured":"Fuglestad MA, Thompson JS. Inflammatory bowel disease and short bowel syndrome. Surg Clin N Am 2019;99:1209\u20131221.","journal-title":"Surg Clin N Am"},{"key":"9125_CR19","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/MIB.0000000000000072","volume":"20","author":"J Lopez","year":"2014","unstructured":"Lopez J, Konijeti GG, Nguyen DD et al. Natural history of Crohn\u2019s disease following total colectomy and end ileostomy. Inflamm Bowel Dis 2014;20:1236\u20131241.","journal-title":"Inflamm Bowel Dis"},{"key":"9125_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.14309\/ajg.0000000000002215","volume":"118","author":"SK Vuyyuru","year":"2023","unstructured":"Vuyyuru SK, Rieder F, Solitano V et al. Patients with Crohn\u2019s disease and permanent ileostomy are universally excluded from clinical trials: a systematic review. Am J Gastroenterol 2023;118:1285\u20131288.","journal-title":"Am J Gastroenterol"},{"key":"9125_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/0016-5085(92)91163-X","volume":"103","author":"E Langholz","year":"1992","unstructured":"Langholz E, Munkholm P, Davidsen M et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444\u20131451.","journal-title":"Gastroenterology"},{"key":"9125_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-biroulet","year":"2010","unstructured":"Peyrin-biroulet L, Loftus EV, Colombel JF et al. The natural history of adult Crohn\u2019s disease in population-based cohorts. Am J Gastroenterol 2010;105:289\u2013297.","journal-title":"Am J Gastroenterol"},{"key":"9125_CR23","volume-title":"Rinvoq [Package Insert]","author":"FDA","year":"2019","unstructured":"FDA. Rinvoq [Package Insert]. Chicago: Abbvie; 2019."},{"key":"9125_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","volume":"59","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Kl\u00fcnder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet 2020;59:531\u2013544.","journal-title":"Clin Pharmacokinet"},{"key":"9125_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cpdd.462","volume":"8","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Zeng J, Marroum PJ et al. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev 2019;8:208\u2013216.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"9125_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-019-0378-y","volume":"21","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Trueman S, Othman AA et al. Development of in vitro\u2013in vivo correlation for upadacitinib extended-release tablet formulation. AAPS J 2019;21:108.","journal-title":"AAPS J"},{"key":"9125_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","volume":"29","author":"DF Evans","year":"1988","unstructured":"Evans DF, Pye G, Bramley R et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035\u20131041.","journal-title":"Gut"},{"key":"9125_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1365-2036.1989.tb00254.x","volume":"3","author":"J Fallingborg","year":"1989","unstructured":"Fallingborg J, Christensen LA, Ingeman-Nielsen M et al. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989;3:605\u2013613.","journal-title":"Aliment Pharmacol Ther"},{"key":"9125_CR29","first-page":"183","volume":"46","author":"J Fallingborg","year":"1999","unstructured":"Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999;46:183\u2013196.","journal-title":"Dan Med Bull"},{"key":"9125_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2036.1990.tb00469.x","volume":"4","author":"J Fallingborg","year":"1990","unstructured":"Fallingborg J, Christensen LA, Ingeman-Nielsen M et al. Gastrointestinal pH and transit times in healthy subjects with ileostomy. Aliment Pharmacol Ther 1990;4:247\u2013253.","journal-title":"Aliment Pharmacol Ther"},{"key":"9125_CR31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/cpt.3359","volume":"116","author":"S Bhatnagar","year":"2024","unstructured":"Bhatnagar S, Schlachter L, Eckert D et al. Pharmacokinetics and exposure\u2013response analyses to support dose selection of upadacitinib in Crohn\u2019s disease. Clin Pharmacol Ther 2024;116:1240\u20131251.","journal-title":"Clin Pharmacol Ther"},{"key":"9125_CR32","unstructured":"Koch-Weser J, Schechter PJ. Slow-release preparations in clinical perspective. In: Drug Absorption, 1981: 217\u2013227."},{"key":"9125_CR33","first-page":"205","volume-title":"Physiology of the Digestive Tract","author":"HW Davenport","year":"1977","unstructured":"Davenport HW. Physiology of the Digestive Tract, 4th edn. Chicago: Year Book Medical Publishers; 1977; 205\u2013215.","edition":"4"},{"key":"9125_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijpharm.2010.04.045","volume":"395","author":"KH Yuen","year":"2010","unstructured":"Yuen KH. The transit of dosage forms through the small intestine. Int J Pharm 2010;395:9\u201316.","journal-title":"Int J Pharm"},{"key":"9125_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1023\/A:1015849700421","volume":"8","author":"AJ Coupe","year":"1981","unstructured":"Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1981;8:360\u2013364.","journal-title":"Pharm Res"},{"key":"9125_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0378-5173(93)90127-2","volume":"97","author":"KH Yuen","year":"1993","unstructured":"Yuen KH, Deshmukh AA, Newton JM et al. Gastrointestinal transit and absorption of theophylline from a multiparticulate controlled release formulation. Int J Pharm 1993;97:61\u201377.","journal-title":"Int J Pharm"},{"key":"9125_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0378-5173(94)00200-O","volume":"114","author":"GM Clarke","year":"1995","unstructured":"Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellets systems of varying density. Int J Pharm 1995;114:1\u201311.","journal-title":"Int J Pharm"},{"key":"9125_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0378-5173(00)00399-9","volume":"201","author":"N Billa","year":"2000","unstructured":"Billa N, Yuen KH, Khader MAA et al. Gamma-scintigraphic study of the gastrointestinal transit in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices. Int J Pharm 2000;201:109\u2013120.","journal-title":"Int J Pharm"},{"key":"9125_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0168-3659(94)00118-E","volume":"34","author":"CJ Kenyon","year":"1995","unstructured":"Kenyon CJ, Hooper G, Tierney D et al. The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation. J Control Release 1995;34:31\u201336.","journal-title":"J Control Release"},{"key":"9125_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0378-5173(84)90191-1","volume":"21","author":"SS Davis","year":"1984","unstructured":"Davis SS, Hardy JG, Taylor MJ et al. The effect of food on the gastrointestinal transit of pellets and an osmotic device (Osmet). Int J Pharm 1984;21:331\u2013340.","journal-title":"Int J Pharm"},{"key":"9125_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11095-008-9749-2","volume":"26","author":"HM Fadda","year":"2009","unstructured":"Fadda HM, McConnell EL, Short MD et al. Meal-induced acceleration of tablet transit through the human small intestine. Pharm Res 2009;26:356\u2013360.","journal-title":"Pharm Res"},{"key":"9125_CR42","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bmj.2.5972.667","volume":"2","author":"GN Tytgat","year":"1975","unstructured":"Tytgat GN, Huibregtse K. Loperamide and ileostomy output\u2013placebo-controlled double-blind crossover study. Br Med J 1975;2:667.","journal-title":"Br Med J"},{"key":"9125_CR43","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1007\/s10620-021-07346-y","volume":"67","author":"AM Wegeberg","year":"2022","unstructured":"Wegeberg AM, Liao D, Jensen SL et al. Gastrocolic reflex is delayed and diminished in adults with type 1 diabetes. Dig Dis Sci 2022;67:4827\u20134833. 10.1007\/s10620-021-07346-y","journal-title":"Dig Dis Sci"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09125-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T07:02:22Z","timestamp":1756969342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09125-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9125"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09125-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.V.L. has consulted for AbbVie, Abivax, Amgen, Astellas, Avalo, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Iota Biosciences, Iterative Scopes, Janssen, Morphic, Ono Pharma, Protagonist, Surrozen, Takeda, and TR1X Bio; has had research support from AbbVie, Genentech, Gilead, Janssen, and Takeda; and is a shareholder of Exact Sciences and Moderna. FAF received consulting fees from Astellas, Avalo Therapeutics, Bausch, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Pharmacosmos, Pfizer, Sandoz Immunology, and Viatris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}